SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This is an open label, dose-seeking phase 1/2 study using escalating doses of TRABECTEDIN
given intravenously with defined doses of IPILIMUMAB and NIVOLUMAB based on preliminary
results of the Checkmate 012 trial for NSCLC (Hellman et al., 2016). For the Phase 1 Part of
Study, only previously treated patients will be enrolled. For the Phase 2 Part of Study,
previously untreated patients will be enrolled.